BioCentury
ARTICLE | Clinical News

Emibetuzumab: Phase II data

May 30, 2016 7:00 AM UTC

Data from 89 evaluable c-MET-positive, metastatic NSCLC patients with acquired resistance to Tarceva in an open-label, international Phase II trial showed that 750 mg IV emibetuzumab given on days 1 a...